Vorinostat unmasks MAEL to enhance DC vaccine-induced CTL killing in hepatocellular carcinoma, potentiated by TIGIT checkpoint inhibition
Cancer Immunology, Immunotherapy · 19.05.2026 · 75 (8)
DOI: 10.1007/s00262-026-04410-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.05.2026. Verfasst von Can Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China. Hauptthemen laut MEDLINE: Vorinostat, Carcinoma, Hepatocellular, T-Lymphocytes, Cytotoxic, Dendritic Cells. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Background
To address the limited immunogenicity and immune evasion in hepatocellular carcinoma (HCC), this study developed a combinatorial immunotherapy strategy combining antigen-specific vaccination, epigenetic modulation, and TIGIT-targeted checkpoint blockade.
Methods
Bioinformatic screening identified the cancer-testis antigen MAEL as a target. HLA-A*02:01-restricted MAEL peptides were used to pulse monocyte-derived dendritic cells (DCs), which primed cytotoxic T lymphocytes (CTLs). The CTL cytotoxicity against HCC cells was tested. HCC cells were treated with the HDAC inhibitor vorinostat to enhance MAEL expression, and its impact on CTL killing was evaluated. The triple combination (MAEL specific CTLs + vorinostat + anti-TIGIT) was tested in HCC xenograft mouse models, with analyses of tumor growth, survival, and immune infiltration.
Results
MAEL was confirmed as an HCC-associated antigen with restricted normal tissue expression. MAEL peptide-pulsed DCs generated potent CTLs with cytotoxicity against HLA-A*02:01⁺ HCC lines. Vorinostat upregulated MAEL expression, enhancing CTL killing ( p < 0.01). In vivo, the dual combination (MAEL specific CTLs + vorinostat) outperformed monotherapies, reducing tumor growth and prolonging survival. The triple combination achieved the strongest anti-tumor effects, with significant regression and extended survival, via increased activated MAEL specific CD8⁺ T cell infiltration and enhanced CTL effector functions (elevated IFN- γ , TNF- α ).
Conclusion
This triple combination strategy synergistically enhances HCC immunotherapy. Vorinostat induces MAEL expression to “unmask” tumors, while TIGIT blockade overcomes T cell exhaustion, amplifying antigen-specific CTL activity. This approach shows promise for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
- Chemical Drug Laboratory, Hebei Institute for Drug and Medical Device Control, Shijiazhuang, 050000, People's Republic of China.
- Hepatology department, The Third Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
- Clinical Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China. zhangjian2221993@126.com.
Förderung
- Natural Science Foundation of Hebei Province
Zitieren
APA
Liu, C., Zhang, Q., Zhang, J., Liu, W., Geng, S., & Zhang, J. (2026). Vorinostat unmasks MAEL to enhance DC vaccine-induced CTL killing in hepatocellular carcinoma, potentiated by TIGIT checkpoint inhibition. Cancer Immunology, Immunotherapy, 75(8). https://doi.org/10.1007/s00262-026-04410-2
Vancouver
Liu C, Zhang Q, Zhang J, Liu W, Geng S, Zhang J. Vorinostat unmasks MAEL to enhance DC vaccine-induced CTL killing in hepatocellular carcinoma, potentiated by TIGIT checkpoint inhibition. Cancer Immunology, Immunotherapy. 2026;75(8). doi:10.1007/s00262-026-04410-2
BibTeX
@article{Liu2026,
author = {Liu, Can and Zhang, Qianru and Zhang, Jingjing and Liu, Wenpeng and Geng, Shengya and Zhang, Jiandong},
title = {Vorinostat unmasks MAEL to enhance DC vaccine-induced CTL killing in hepatocellular carcinoma, potentiated by TIGIT checkpoint inhibition},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {8},
doi = {10.1007/s00262-026-04410-2}
}
EUVIMED